Does the media refer more to ARWR or RVMD?

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.73 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ARWR or ONC?

In the previous week, BeOne Medicines had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 14 mentions for BeOne Medicines and 12 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat BeOne Medicines' score of 0.33 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRNA or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Moderna. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 11 mentions for Moderna. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat Moderna's score of 0.15 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or ROIV?

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arrowhead Pharmaceuticals (ARWR) Competitors

$74.30 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$74.72 +0.42 (+0.57%)

As of 04:07 AM Eastern

Compare

ARWR vs. RVMD, TEVA, ONC, MRNA, and ROIV

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? MarketBeat compares Arrowhead Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arrowhead Pharmaceuticals include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Arrowhead Pharmaceuticals currently has a consensus price target of $88.75, suggesting a potential upside of 19.45%. Revolution Medicines has a consensus price target of $144.00, suggesting a potential downside of 22.65%. Given Arrowhead Pharmaceuticals' higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.62	-$1.63M	-$2.15	N/A
Revolution Medicines	$11.58M	3,417.76	-$1.13B	-$7.07	N/A

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.73 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Revolution Medicines	N/A	-83.22%	-59.06%

Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Teva Pharmaceutical Industries has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.62	-$1.63M	-$2.15	N/A
Teva Pharmaceutical Industries	$17.26B	2.13	$1.41B	$1.33	24.06

Arrowhead Pharmaceuticals currently has a consensus target price of $88.75, indicating a potential upside of 19.45%. Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 30.57%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 12 mentions for Arrowhead Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

In the previous week, BeOne Medicines had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 14 mentions for BeOne Medicines and 12 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat BeOne Medicines' score of 0.33 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BeOne Medicines' return on equity of 12.06% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
BeOne Medicines	8.94%	12.06%	6.69%

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals currently has a consensus target price of $88.75, indicating a potential upside of 19.45%. BeOne Medicines has a consensus target price of $390.92, indicating a potential upside of 25.29%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.62	-$1.63M	-$2.15	N/A
BeOne Medicines	$5.34B	6.41	$286.93M	$4.47	69.80

Summary

BeOne Medicines beats Arrowhead Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Moderna presently has a consensus target price of $38.27, suggesting a potential downside of 38.10%. Arrowhead Pharmaceuticals has a consensus target price of $88.75, suggesting a potential upside of 19.45%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Moderna. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.62	-$2.82B	-$8.15	N/A
Arrowhead Pharmaceuticals	$829.45M	12.62	-$1.63M	-$2.15	N/A

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Moderna. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 11 mentions for Moderna. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat Moderna's score of 0.15 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Moderna has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Arrowhead Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.62	-$1.63M	-$2.15	N/A
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat Arrowhead Pharmaceuticals' score of 0.73 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals currently has a consensus price target of $88.75, indicating a potential upside of 19.45%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 2.66%. Given Arrowhead Pharmaceuticals' higher possible upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.47B	$3.69B	$6.86B	$12.27B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-34.56	21.21	27.26	23.92
Price / Sales	12.62	304.52	581.28	113.62
Price / Cash	622.28	60.31	29.05	48.09
Price / Book	20.41	8.28	10.61	6.18
Net Income	-$1.63M	$23.81M	$3.59B	$331.89M
7 Day Performance	0.26%	-1.34%	-1.01%	-1.22%
1 Month Performance	-9.19%	2.68%	1.65%	-1.30%
1 Year Performance	343.32%	45.93%	25.62%	17.74%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	3.1169 of 5 stars	$74.30 flat	$88.75 +19.4%	+343.3%	$10.47B	$829.45M	N/A	400	Positive News Analyst Forecast
RVMD Revolution Medicines	1.9897 of 5 stars	$183.95 -1.6%	$144.00 -21.7%	+386.1%	$39.73B	$11.58M	N/A	250
TEVA Teva Pharmaceutical Industries	4.8081 of 5 stars	$32.15 -2.4%	$41.78 +29.9%	+99.0%	$37.89B	$17.26B	24.17	33,950	Positive News
ONC BeOne Medicines	4.6838 of 5 stars	$303.96 +1.8%	$391.38 +28.8%	+5.9%	$32.77B	$5.34B	68.00	12,000	Analyst Upgrade
MRNA Moderna	1.7293 of 5 stars	$67.01 -1.8%	$38.27 -42.9%	+97.8%	$27.09B	$1.94B	N/A	4,700	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Moderna?

Summary

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Do analysts recommend ARWR or RVMD?

Which has higher valuation & earnings, ARWR or RVMD?

Does the media refer more to ARWR or RVMD?

Is ARWR or RVMD more profitable?

Which has more risk & volatility, ARWR or RVMD?

Do insiders and institutionals have more ownership in ARWR or RVMD?

Summary

How does Arrowhead Pharmaceuticals compare to Teva Pharmaceutical Industries?

Which has stronger earnings and valuation, ARWR or TEVA?

Do analysts recommend ARWR or TEVA?

Does the media refer more to ARWR or TEVA?

Which has more risk & volatility, ARWR or TEVA?

Is ARWR or TEVA more profitable?

Do insiders and institutionals believe in ARWR or TEVA?

Summary

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Which has more risk & volatility, ARWR or ONC?

Does the media refer more to ARWR or ONC?

Is ARWR or ONC more profitable?

Do insiders and institutionals believe in ARWR or ONC?

Do analysts rate ARWR or ONC?

Which has higher valuation & earnings, ARWR or ONC?

Summary

How does Arrowhead Pharmaceuticals compare to Moderna?

Do analysts recommend MRNA or ARWR?

Which has higher valuation and earnings, MRNA or ARWR?

Does the media favor MRNA or ARWR?

Do institutionals and insiders hold more shares of MRNA or ARWR?

Is MRNA or ARWR more profitable?

Which has more risk & volatility, MRNA or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Which has better earnings & valuation, ARWR or ROIV?

Does the media refer more to ARWR or ROIV?

Is ARWR or ROIV more profitable?

Do institutionals and insiders have more ownership in ARWR or ROIV?

Do analysts recommend ARWR or ROIV?

Which has more volatility and risk, ARWR or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools